EndoChoice Holdings, Inc., a medtech company, announced the full market release of its Generation 3 Full Spectrum Endoscopy (Fuse) system. Fuse Generation 3 includes an ergonomically advanced control body, incorporating over 50 system enhancements and a novel Adaptive Matrix Imaging technology called Lumos, that enables physicians to see more with enhanced clarity. The company is beginning sales and distribution of Generation 3 scopes in the United States, European Union, and other select markets.

Lumos Adaptive Matrix Imaging takes a revolutionary approach to enhance the view of the mucosal structures and vascular patterns in their natural color and the ability for "always-on" functionality via smart enhancement technology, making it the first advanced imaging solution designed to improve the entire procedure.  Lumos is now launched in Europe with the CE mark, and is pending FDA clearance in the United States.

Commenting on the new product release, Dr Booker Dalton, Gastroenterologist at Digestive Healthcare of Georgia, said "Fuse Generation 3 is a significant advancement of the Full Spectrum Endoscopy system. Fuse's new ergonomic design and system refinements greatly enhance the overall user experience. Coupled with its already impressive 330-degree field of view and published clinical value, Fuse is a game changer."   

Mark Gilreath, founder and CEO of EndoChoice, stated, "We are truly excited to bring Fuse Generation 3 and Lumos to the world of GI. With Generation 3, not only do GI's have an increased field of view to help detect lesions, they now have the ability to enhance anatomy like never before with Lumos Adaptive Matrix Imaging.  We believe these advancements take the Fuse platform to an unprecedented level in endoscopic screening."

Based near Atlanta, Georgia, EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer.